MIV Therapeutics establishes U.S. corporate headquarters

By E. Janene Geiss

Philadelphia, May 5 - MIV Therapeutics announced Friday that it established an official U.S. headquarters with the opening of a new corporate office in Atlanta.

The new office will be dedicated to reinforcing business and research opportunities and relationships in the United States, according to a company news release.

Its establishment follows the company's recent appointment of Mark Landy, a former Wall Street medical device analyst, as the president of the company. Landy will be based in the Atlanta office, officials said.

"Our new U.S. office will be dedicated to raising our profile and establishing new strategic partnerships," Alan Lindsay, chief executive officer, said in the release.

MIV is a developer of unique, ultra-thin biocompatible and polymer-free coatings for vascular stents, internal drug delivery systems and other medical applications. Its first product line will be launched in 2007 and will target the estimated $160 billion marketplace for localized drug delivery technologies, officials said.

Along with the new Atlanta office, MIV is based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.